Cipla announced on Wednesday that it has received approval from the US Food and Drug Administration (USFDA) to market a generic medication used to treat acromegaly and other related conditions. The approval includes multiple strengths of Lanreotide injection, a therapeutic equivalent generic version of Somatuline Depot Injection.
At the time of writing, the shares of Cipla were trading at ₹1500.15 which is a 1.20% gain than the previous close. The stock has gained over 61.24% in the last one year, and 19.90% since the beginning of the year.
Lanreotide Injection is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumors. Somatuline Depot, the branded version, had sales of approximately USD 898 million in the US for the 12-month period ending March 2024, according to IQVIA (IMS Health).
For feedback and suggestions, write to us at editorial@iifl.com
For opening a demat account click on: https://www.indiainfoline.com/
For doing stock trading & investments, go to: https://ttweb.indiainfoline.com/trade/Login.aspx
For loans, go to: https://www.iifl.com/
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.